"I sense management don't consider its shareholders interests when making these decisions."
Personally, I would characterize it as management taking the appropriate decisions to continue expanding the range and scope of clinical trials to bring about multiple opportunities for commercialisation of the co's IP.
Ultimately, that's certainly in the shareholders interests.
.
Ann: Immutep completes a A$29.6 million placement, page-17
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2506 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 8079 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |